Evogene (NASDAQ:EVGN – Get Free Report) and BioCardia (NASDAQ:BCDA – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.
Valuation and Earnings
This table compares Evogene and BioCardia”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evogene | $3.85 million | 0.84 | -$8.48 million | ($0.91) | -0.41 |
| BioCardia | $60,000.00 | 234.42 | -$8.23 million | ($0.64) | -1.45 |
BioCardia has lower revenue, but higher earnings than Evogene. BioCardia is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Evogene and BioCardia, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evogene | 1 | 0 | 0 | 0 | 1.00 |
| BioCardia | 1 | 1 | 1 | 0 | 2.00 |
BioCardia has a consensus target price of $25.00, indicating a potential upside of 2,591.07%. Given BioCardia’s stronger consensus rating and higher probable upside, analysts plainly believe BioCardia is more favorable than Evogene.
Volatility and Risk
Evogene has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.
Insider & Institutional Ownership
10.4% of Evogene shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 7.4% of Evogene shares are held by insiders. Comparatively, 17.4% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Evogene and BioCardia’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evogene | -694.18% | -156.53% | -86.80% |
| BioCardia | N/A | -569.36% | -183.15% |
Summary
BioCardia beats Evogene on 9 of the 14 factors compared between the two stocks.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
